Abstract | Purpose: Topical application of levodopa inhibits the development of form-deprivation myopia (FDM) and lens-induced myopia (LIM) in chicks. Here we examine whether coadministration with carbidopa enhances this protection and compare the effectiveness of topical versus systemic administration. We also investigate the degree to which topical and systemic administration of these compounds alters retinal dopamine release and examine whether this is the mechanism by which they inhibit experimental myopia. Methods: Results: Conclusions: The presence of carbidopa increases the bioavailability of levodopa within the eye, enhancing its antimyopic effects, with topical application showing the greatest efficacy. Thus levodopa: carbidopa may be a promising treatment for controlling the progression of human myopia.
|
Authors | Kate Thomson, Ian Morgan, Tamsin Kelly, Cindy Karouta, Regan Ashby |
Journal | Investigative ophthalmology & visual science
(Invest Ophthalmol Vis Sci)
Vol. 62
Issue 4
Pg. 25
(04 01 2021)
ISSN: 1552-5783 [Electronic] United States |
PMID | 33877264
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Dopamine Agents
- Drug Combinations
- Ophthalmic Solutions
- carbidopa, levodopa drug combination
- Levodopa
- Carbidopa
- Dopamine
|
Topics |
- Administration, Topical
- Animals
- Animals, Newborn
- Biomarkers
(metabolism)
- Carbidopa
(administration & dosage)
- Chickens
- Disease Models, Animal
- Dopamine
(metabolism)
- Dopamine Agents
(administration & dosage)
- Dose-Response Relationship, Drug
- Drug Combinations
- Injections, Intraperitoneal
- Levodopa
(administration & dosage)
- Male
- Mitosis
(drug effects)
- Myopia
(drug therapy, metabolism, pathology)
- Ophthalmic Solutions
- Sensory Deprivation
- Vitreous Body
(metabolism, pathology)
|